RxDoctor Payments Data

Steven Corse, DO

Family Medicine · Highland, INNPI 1750356978

Payments from drug & device makers

$1,373in general payments, 2019–2025

Across 51 payments — averaging $26.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$293
  • Pfizer$218
  • Amgen$214
  • AbbVie$181
  • AstraZeneca$172
  • Almatica Pharma LLC$64
  • plus $231 from 10 others

What the payments were for

  • Food & beverage$1,373100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,373 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$38,319
Medicare patients
83
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$51,272
OxycontinOxycodone Hcl26$35,051
JardianceEmpagliflozin15$25,456
MounjaroTirzepatide15$19,740
TrulicityDulaglutide12$11,538
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen271$7,983
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen93$3,970
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,214
Albuterol Sulfate HfaAlbuterol Sulfate45$1,840
Celecoxib14$1,257
Oxycodone Hcl33$1,071
Alprazolam198$998
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine40$953
Levothyroxine Sodium107$892
Lisinopril81$837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$30$51,27251 claims
Lilly USA, LLCMounjaro, Trulicity$20$31,27827 claims
Boehringer IngelheimJardiance$42$25,45615 claims
AbbVieSynthroid$181$69819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Highland

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →